 |
 |
 |
Pipeline |
|
|
Epigenomics AG Product Pipeline Analysis
Publication Date August 2008
Publisher Global Markets Direct
Product Type Report
Pages 47
ISBN Number not applicable
Product Code GMD624
|
|
|
Summary
This report is an insightful source for data, analysis and strategic insights into a Epigenomics AG's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.
Scope
- Details of development stage by sector and equipment type.
- Pipeline products grouped by therapy area, development stage and trial phase.
- Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
- Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
- Product updates covering estimated approval dates and estimated launch dates.
- Descriptions of novel technologies relating to pipeline products of the company.
- Patents and patent applications covered for the product.
- News updates on key events relating to the product and its development.
Reasons to buy
- A single source to fulfill competitor information relating to products in development.
- Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
- Access clinical trial information to map trial results and plan targeted marketing activities.
- Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
- Identification of potential investment opportunities.
- Build up knowledge base for potential distribution and marketing partners.
- Helps avoid patent infringement.
- Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.
|
Content
- 1 List of Tables
- 2 Company Snapshot
- 2.1 Key Information
- 2.2 Company Overview
- 2.3 Financial Performance
- 2.4 Industry Outlook - In Vitro Diagnostics
- 3 Business Description
- 3.1 Business Overview
- 3.2 Major Products and Services
- 4 Competitors
- 5 Key Employees
- 6 Key Employee Biographies
- 7 Company Statement
- 8 Locations And Subsidiaries
- 8.1 Head Office
- 8.2 Other Locations & Subsidiaries
- 9 Recent Developments
- 9.1 Strategy And Business Planning
- 9.1.1 Jan 14, 2008: Epigenomics Enters Into Strategic Cross-Licensing Agreement With DxS
- 9.1.2 Jan 14, 2008: Epigenomics Issues Technology Licenses To OncoMethylome
- 9.1.3 Sep 26, 2007: Epigenomics Signs Agreement With Abbott
- 9.1.4 May 09, 2007: Epigenomics Enters R&D Collaboration With Myriad
- 9.1.5 Apr 12, 2007: Epigenomics Forms Alliance With Clinical Data For DNA Methylation Services
- 9.2 Financial Announcements
- 9.2.1 Aug 05, 2008: Epigenomics Reports 1H 2008 Results
- 9.2.2 May 06, 2008: Epigenomics Reports Q1 2008 Results
- 9.2.3 Mar 31, 2008: Epigenomics Reports 2007 Results
- 9.2.4 Mar 13, 2008: Epigenomics To Declare 2007 Results
- 9.2.5 Oct 31, 2007: Epigenomics Declares Q3 2007 Results
- 9.2.6 Aug 02, 2007: Epigenomics Declares H1 2007 Results
- 9.2.7 May 03, 2007: Epigenomics Declares Q1 2007 Results
- 9.2.8 Mar 30, 2007: Epigenomics Declares 2006 Results
- 9.3 Research And Development
- 9.3.1 May 09, 2007: Epigenomics Enters R&D Collaboration With Myriad
- 9.4 Corporate Communications
- 9.4.1 Aug 05, 2008: Epigenomics Announces Management Changes
- 9.4.2 Jan 21, 2008: Epigenomics Appoints New Advisory Board Member
- 9.4.3 Jan 16, 2008: Epigenomics Appoints New CEO
- 9.5 Product News
- 9.5.1 Apr 21, 2008: Epigenomics AG Successfully Validates Optimized Blood-Based Colorectal Cancer Assay In Two Independent Clinical Studies
- 9.5.2 Apr 14, 2008: Epigenomics AG Presents Data on Novel Prostate Cancer Biomarkers at AACR
- 9.5.3 Feb 19, 2008: Epigenomics Licenses Septin 9 Colorectal Cancer Biomarker To Quest Diagnostics
- 9.6 Clinical Trials
- 9.6.1 Apr 21, 2008: Epigenomics AG Successfully Validates Optimized Blood-Based Colorectal Cancer Assay In Two Independent Clinical Studies
- 10 Epigenomics AG Pipeline Products
- 10.1 Epigenomics AG Product Pipeline Analysis
- 10.1.1 Epigenomics AG Pipeline Products By Equipment Type
- 10.1.2 Epigenomics AG Pipeline Products By Development Stage
- 10.1.3 Epigenomics AG Pipeline Products By Therapy Area
- 10.1.4 Epigenomics AG Pipeline Products By Clinical Trials
- 10.1.5 Epigenomics AG Pipeline Products By News Summary
- 10.2 Colorectal cancer screening test
- 10.2.1 Product Description
- 10.2.2 Product Status
- 10.2.3 Clinical Trials
- 10.2.4 Product Milestone
- 10.3 Prostate Cancer Screening Test
- 10.3.1 Product Description
- 10.3.2 Product Status
- 10.3.3 Product Milestone
- 10.4 Lung Cancer Screening Test
- 10.4.1 Product Description
- 10.4.2 Product Status
- 10.4.3 Clinical Trials
- 10.4.4 Product Milestone
- 11 Appendix
- 11.1 Methodology
- 11.1.1 Coverage
- 11.1.2 Secondary Research
- 11.1.3 Primary Research
- 11.1.4 Expert Panel Validation
- 11.2 Contact Us
- 11.3 About Global Markets Direct
- 11.4 Disclaimer
- 1 List of Tables
- Table 1: Epigenomics AG,Key Facts
- Table 2: Epigenomics AG, Key Employees,
- Table 3: Epigenomics AG, Other Locations
- Table 4: Epigenomics AG, Subsidiaries
- Table 5: Epigenomics AG Pipeline Products by Equipment Type
- Table 6: Epigenomics AG Pipeline Products By Development Stage
- Table 7: Epigenomics AG Pipeline Products By Therapy Area
- Table 8: Epigenomics AG Pipeline Products By Clinical Trials
- Table 9: Epigenomics AG Pipeline Products By News Summaries
- 1.2 List of Figures
- Figure 1: Epigenomics AG Pipeline Products By Development Stage
- Figure 2: Epigenomics AG Pipeline Products By News Summary
- Figure 3: Global Markets Direct Methodology
|
|
| Scope |
Expert Insight/Opinion |
|
| Profiles |
In-depth Company Insight |
|
| Features |
Primary Research Data |
|
|